Formulation and Evaluation of Pantoprazole Delayed Release Tablets using Eudragit L30D55

Kanakagiri, Divakar; Omprakash, Hari; M, Kishore Kumar; Yerragunta, Vishwanadham

doi:10.5958/0974-360x.2017.00084.1

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These systems mechanically control drug release in a précise and predetermined manner to maintain drug plasma levels for a prolonged period [11]. The matrix-based systems are most commonly used due to their efficacy and convenience [12]. The methocel ® is white or off white powder [13].…”

Section: Introductionmentioning

confidence: 99%

Estimation of Quality Characteristics for Sustained Releasing and Acting Formulation of Domperidone

Zeb-un-Nisa¹,

Ali²,

Shahnaz³

et al. 2021

Pharmacophore

View full text Add to dashboard Cite

The present study aimed to design a sustained releasing and acting formulation of Domperidone with the aid of hydrophilic Methocel® K4M. Domperidone is an antiemetic drug used to treat nausea and vomiting. Generally, the dosing frequency is twice or thrice daily. Sustained-release formulation was prepared with different ratios of K4M. Furthermore, its quality and stability were determined. Pre-compression and post-compression characteristics were examined and the optimized formulation was selected for dissolution studies and also for similarity profiles. Drug dissolution studies revealed formulated tablet containing CF2 depicted the ideal release profile for once-daily consumption. Long-acting domperidone matrices were not just prepared but also displayed desirable properties required for an ideal once-daily formulation. The mechanism might be gel layer formation which afterward proceeded by gel erosion, hence giving a long slowreleasing pattern and desirable therapeutic effect. The concept of controlled release formulations helps the patients and care givers by reducing dosing frequency and chances of missed doses or overnight gap in administration of dose.

show abstract

Section: Introductionmentioning

confidence: 99%

Estimation of Quality Characteristics for Sustained Releasing and Acting Formulation of Domperidone

Zeb-un-Nisa¹,

Ali²,

Shahnaz³

et al. 2021

Pharmacophore

View full text Add to dashboard Cite

show abstract

Influence of different viscosity grade cellulose-based polymers on the development of valsartan controlled release tablets

et al. 2019

View full text Add to dashboard Cite

Formulation design and Evaluation of Extended-Release Tablets of Oxybutynin for Effective Management of Overactive Bladder Syndrome

Nandhakumar

Sugreevudu

Harikrishnan

2021

RJPT

View full text Add to dashboard Cite

Overactive bladder syndrome (OAB) is a chronic condition with a composite of symptoms and has a significant negative impact on the physiological and psychological well-being of the patients. The present study is aimed at developing extended-release formulations of oxybutynin that is effective in reducing the side effects associated with the drug by maintaining a steady state concentration with minimal fluctuations in plasma drug concentration and thereby achieves improved patient compliance. The extended-release drug delivery of tablets can be achieved by preparing the matrix tablet of oxybutynin chloride with klucel HF in core tablet by wet granulation technique and functional coating with a combination of aquacoat ECD-30 and hypromellose E5 followed by film coating with opadry. For confirmation of compatibility, the pure drug and its physical mixtures were subjected to FTIR studies. All the formulations have shown acceptable limits in all precompression and post compression parameters. The in vitro release studies in 0.1N HCl and 6.8 phosphate buffer revealed that the optimized formulation F10 extend the release of the drug to 91% at 24 hours and the release profile was similar to the innovator’s product as revealed by the similarity factor study. The release kinetics study revealed that the release of the drug followed diffusion mechanism. Stability studies of the selected formulation tablets were carried out at 25°C ±2°C/60% RH±5% and 40°C ±2°C /75%±5% RH for different time period and all the parameter was within the limits after storage period. Thus the extended release matrix tablets of oxybutynin chloride developed in this study have immense potential to develop into a marketed product following the testing in animals and human volunteers.

show abstract

Formulation and Evaluation of Pantoprazole Delayed Release Tablets using Eudragit L30D55

Cited by 4 publications

References 0 publications

Estimation of Quality Characteristics for Sustained Releasing and Acting Formulation of Domperidone

Estimation of Quality Characteristics for Sustained Releasing and Acting Formulation of Domperidone

Influence of different viscosity grade cellulose-based polymers on the development of valsartan controlled release tablets

Formulation design and Evaluation of Extended-Release Tablets of Oxybutynin for Effective Management of Overactive Bladder Syndrome

Contact Info

Product

Resources

About